drugset / Trial / NCT02101164

Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease

NCT02101164

Phase 4 Withdrawn Amgen
RandomizedCrossoverOpen-label

Summary

This study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.

Timeline

Start
2014-11
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody 120 mg Subcutaneous
Comparator Pamidronate Small molecule 90 mg Intravenous